Name of this trial: ASC2ESCALATE
What type of cancer is this for? CML (Chronic Myeloid Leukemia)
Who is this trial for? Men and women with chronic myeloid leukemia without T315I mutation who have had one prior ATP-binding site TKI (tyrosine kinase inhibitors) that was stopped because it stopped working or the side effects were too hard to take.
What biomarkers are involved? You must NOT have a T315I mutation.
National Clinical Trial # NCT05384587
Brief summary of this trial: This trial is looking to see how effective Asciminib is in patients with CML, as a second drug that they get to treat it.
Need to know: You need to have tried a TKI (tyrosine kinase inhibitor) like Sprycel or Tarceva and then stopped taking it.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065